Affini-T Therapeutics, a cell therapy company spun out of Fred Hutchinson Cancer Research Center that aims to treat solid tumors, is closing its Seattle lab.
- Multiple impacted employees posted on LinkedIn about the Seattle office shutting down.
- A company spokesperson confirmed the closure to GeekWire. The news was first reported by Endpoints News, which said the company has 17 employees in Seattle. Some were offered the option to relocate to the company’s Boston headquarters.
- Affini-T raised $175 million last year as it came out of stealth mode. The 80-person company is developing cancer treatments using a strategy called T cell receptor (TCR) cancer immunotherapy. The method involves engineering immune T cells to recognize tumor cells and infusing them into the patient.
- Affini-T is founded on technology developed by Philip Greenberg, Fred Hutch head of immunology, and two other Hutch investigators, co-founders Thomas Schmitt and Aude Chapuis.
